HFpEF Pharmacotherapy: What a Network Meta-analysis Compared
This network meta-analysis compared established and emerging pharmacotherapies evaluated in randomised trials of heart failure with preserved ejection fraction (HFpEF).
Cardiovascular Pharmacotherapy
AllCardiovascular PharmacotherapyClinical Trials and StudiesEvidence-Based MedicineGeneral Cardiac NewsHealthcare Policy and Cardiovascular CareHeart Failure InsightsResearch
Dapagliflozin Started During Heart Failure Hospitalisation: DAPA ACT HF-TIMI 68
DAPA ACT HF-TIMI 68 tested in-hospital initiation of dapagliflozin 10 mg daily in 2,401 patients hospitalised for heart failure.
Ferric Carboxymaltose in Heart Failure With Iron Deficiency: FAIR-HF2
FAIR-HF2 evaluated the efficacy and safety of intravenous ferric carboxymaltose in people with heart failure, left ventricular ejection fraction of 45% or less and iron deficiency.
Tirzepatide in HFpEF With Obesity: Results From the SUMMIT Trial
SUMMIT enrolled 731 people with HFpEF and obesity to compare tirzepatide with placebo for at least 52 weeks.
Finerenone After Recent Worsening Heart Failure: A FINEARTS-HF Analysis
This FINEARTS-HF analysis examined finerenone in people with heart failure and left ventricular ejection fraction of at least 40%, according to how recently a worsening heart failure event…